OnKommon - Global Header
OnKommon.
Home
Blueprint Overview
Explore the core clinical ecosystem
Flagship Program
Blueprint Care
Your Signature decision report, executed by a dedicated clinical team.
Starting Points
Signal Free
4-hour WhatsApp triage
Navigation
Clarity timeline + roadmap (no test)
Signature Overview
Comprehensive molecular profiling testing options
Solid Tumour (S)
Signature STb 33-gene blood Signature STb O 118-gene blood Signature STb O+ CGP Flagship
Signature STt O FFPE Tissue
Blood Cancer (B)
Signature B ALL Lymphoblastic Leukaemia Signature B AML Myeloid Leukaemia
Complete the Journey
Execute with Blueprint Care
Decipher Overview
Turn existing data into a decision. No new test required.
Decipher
Full interpretation
Decipher Plus
Top-up missing gaps + interpretation
The Fastest Route In
Enter Blueprint Care
Heritage Overview
Germline risk from blood/saliva
Heritage Core
Index/Proband
Heritage Adhoc
Cascade tracking
Clear Overview
Molecular residual disease
Clear Blood
Clear Solid
Sentinel Overview
Treatment monitoring via serial testing
Sentinel Blood
Sentinel Solid
Clinicians
Ordering & MTB
Industry
Trials & Evidence
Research
Data & Collaboration
Technology (Engine)
Pipeline
Governance
About Us
KPCIRC Partner
Contact
Get Started
Heritage Adhoc – Focused Cascade Testing for Families · OnKommon
Heritage · Adhoc

Heritage Adhoc — Focused cascade testing for families.

HERITAGE · FOCUSED CASCADE TESTING FOR FAMILIES

Heritage Adhoc is a focused test for a specific, already-known variant — the tool for cascade testing. When one family member is found (through Heritage Core or elsewhere) to carry an inherited cancer-risk variant, their blood relatives can be tested precisely for that one change.

Learn How It Works ₹35,000 per member
Why Cascade Testing Matters

One finding can protect many.

A single inherited variant can run through a family. Cascade testing lets relatives learn whether they carry it — so those who do can start earlier screening or prevention, and those who do not can be reassured. It is one of the highest-impact, most cost-effective things a family can do after an inherited variant is found.

How It Works

How it works

A variant is identified → Relatives are offered testing → A focused test → A plan for each person

1
Identify

Variant is identified

Someone in the family is found to carry a specific inherited variant.

2
Offer

Relatives are offered testing

With their own consent and genetic counselling, blood relatives can be tested.

3
Test

A focused test

Heritage Adhoc checks precisely for that one known variant — ₹35,000 per member.

4
Plan

A plan for each person

Carriers get a screening/prevention plan; non-carriers get clarity.

Terminology

TERMINOLOGY ON THIS PAGE

The words you will see, in plain language

Term / What it means
GermlineAn inherited change, present from birth and passable to children.
SomaticA change that arises in the tumour during life; not inherited.
Pathogenic variant (PV)A change known to be disease-causing — here, one that raises cancer risk.
VUSVariant of uncertain significance — a change whose meaning is not yet clear.
PenetranceHow likely a person carrying a variant is to actually develop the cancer.
Cascade testingTesting a patient’s blood relatives for a known family variant.
Important information about this test

Heritage Adhoc is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.

  • • A result is not a diagnosis and does not by itself decide treatment.
  • • A “not detected” or normal result does not rule out cancer or a genetic change.
  • • Not all cancers release enough DNA into blood to be detected.
  • • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
  • • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
  • • Confirmatory testing may be required.

Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.

Take the next step

Every OnKommon page offers three ways forward. Choose the one that fits where you are today.

Book a free Blueprint Consultation

A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.

Book now →

Begin Blueprint Care

Commission your decision report and dedicated clinical team.

Get started →

Free WhatsApp guidance (Signal)

A 4-hour triage reply to your first question, at no cost.

Start WhatsApp triage →
Scroll to Top